达瑞生物 (832705.OC)

+ 收藏

利润表(达瑞生物)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年中报2023年年报2023年中报2022年年报2022年中报
上市前/上市后 上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 103,957,692.49200,282,184.30102,524,247.63454,184,906.06206,440,662.82
 营业收入(元) 103,957,692.49200,282,184.30102,524,247.63454,184,906.06206,440,662.82
二、营业总成本(元) 101,009,328.11226,445,397.41119,852,478.38414,512,882.57190,351,645.84
 营业成本(元) 58,528,214.10111,396,505.2559,311,605.71269,662,781.16125,150,411.63
 研发费用(元) 16,713,546.4541,976,661.0121,214,465.0150,496,111.6922,165,665.27
 营业税金及附加(元) 486,956.661,121,309.07563,675.712,089,550.401,162,940.45
 销售费用(元) 16,044,047.7643,762,743.9621,984,912.3057,059,343.4426,764,905.89
 管理费用(元) 11,787,769.5331,776,915.4917,848,679.2337,442,073.4116,869,694.60
 财务费用(元) -2,551,206.39-3,588,737.37-1,070,859.58-2,236,977.53-1,761,972.00
  其中:利息费用(元) 352,075.19368,626.61309,890.92414,191.40166,909.92
  其中:利息收入(元) 2,910,157.353,924,587.021,179,865.942,617,303.351,920,658.03
三、其他经营收益
 加:公允价值变动收益(元) -328,555.93-5,824,592.53--2,377,077.84159,844.59
 加:投资收益(元) 1,526,871.53839,649.82-3,822,791.65-4,030,964.20-2,376,652.97
  其中:对联营企业和合营企业的投资收益(元) 109,610.12-436,762.30-4,402,351.36-6,554,107.40-3,418,290.42
 资产处置收益(元) --95,354.76---
 资产减值损失(元) -302,223.72-32,040,378.67--16,761,479.69-
 信用减值损失(元) -2,314,688.33-3,548,459.03-1,087,795.11-3,140,318.5098,094.70
 其他收益(元) 2,447,922.414,649,110.393,542,964.945,563,711.624,203,928.58
四、营业利润(元) 3,977,690.34-62,183,237.89-18,695,852.5718,925,894.8818,174,231.88
 加:营业外收入(元) 9.363,073.017,941.6351,960.23583.69
 减:营业外支出(元) 449,902.113,325,063.411,769,091.05245,186.5064,452.75
五、利润总额(元) 3,527,797.59-65,505,228.29-20,457,001.9918,732,668.6118,110,362.82
 减:所得税费用(元) 351,130.1419,232,543.86-4,945,082.49-1,536,726.842,129,364.10
六、净利润(元) 3,176,667.45-84,737,772.15-15,511,919.5020,269,395.4515,980,998.72
(一)按经营持续性分类
  持续经营净利润(元) 3,176,667.45-84,737,772.15-15,511,919.5020,269,395.4515,980,998.72
(二)按所有权归属分类
  归属于母公司股东的净利润(元) 3,217,299.01-84,497,451.88-15,445,779.0920,648,194.1116,188,321.56
  少数股东损益(元) -40,631.56-240,320.27-66,140.41-378,798.66-207,322.84
 扣除非经常性损益后的净利润(元) 2,431,267.81-80,301,940.09-17,219,416.1116,068,119.2611,651,281.42
七、每股收益
 一、基本每股收益(元) 0.01-0.30-0.060.070.06
 二、稀释每股收益(元) 0.01-0.30-0.060.070.06
八、其他综合收益(元) 136,014.28136,014.28310,584.36794,811.30390,085.50
 归属于母公司股东的其他综合收益(元) 138,612.01138,612.01310,584.36805,835.24390,085.50
 归属于少数股东的其他综合收益(元) -2,597.73-2,597.73--11,023.94-
九、综合收益总额(元) 3,312,681.73-84,601,757.87-15,201,335.1421,064,206.7516,371,084.22
 归属于母公司所有者的综合收益总额(元) 3,355,911.02-84,358,839.87-15,135,194.7321,454,029.3516,578,407.06
 归属于少数股东的综合收益总额(元) -43,229.29-242,918.00-66,140.41-389,822.60-207,322.84
公告日期 2024-08-302024-03-292023-08-302023-03-302022-08-29
审计意见(境内) 标准无保留意见标准无保留意见
原始财报文件下载 下载财报(PDF)下载财报(PDF)下载财报(PDF)下载财报(PDF)下载财报(PDF)

前瞻产业研究院